- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 19.05. | OKYO Pharma appoints Marta Sacchetti to advisory board | 2 | Investing.com | ||
| OKYO PHARMA Aktie jetzt für 0€ handeln | |||||
| 19.05. | OKYO Pharma LTD: OKYO Expands Scientific Advisory Board with the Appointment of International Expert Marta Sacchetti, MD, PhD | 368 | GlobeNewswire (Europe) | Dr. Sacchetti brings international expertise in clinical and translational research on ocular inflammatory and degenerative diseaseOKYO's introduction to the broader ophthalmology community at ASCRS... ► Artikel lesen | |
| 19.05. | OKYO Pharma Ltd - 6-K, Report of foreign issuer | 1 | SEC Filings | ||
| 29.04. | OKYO Pharma LTD: OKYO CEO and CSO to Present and Leadership Team to Participate at Upcoming Scientific Conferences in May | 371 | GlobeNewswire (Europe) | Robert J. Dempsey, MBA, Chief Executive Officer, to present at EyeceleratorRaj Patil, PhD, Chief Scientific Officer, to present at ARVO
LONDON and NEW YORK, April 29, 2026 (GLOBE NEWSWIRE) -- OKYO... ► Artikel lesen | |
| 29.04. | OKYO Pharma Ltd - 6-K, Report of foreign issuer | 2 | SEC Filings | ||
| 07.04. | OKYO Pharma beruft Expertengremium zu Medikamentenkandidat Urcosimod ein | 3 | Investing.com Deutsch | ||
| 07.04. | OKYO Pharma plant Expertentreffen zu Urcosimod auf ASCRS-Jahrestagung | 1 | Investing.com Deutsch | ||
| 07.04. | OKYO Pharma to hold advisory board meeting at ASCRS conference | 1 | Investing.com | ||
| 07.04. | OKYO Pharma Announces Scientific Advisory Board Meeting and Urcosimod Data Presentation During ASCRS Annual Meeting | 331 | GlobeNewswire (Europe) | LONDON and NEW YORK, April 07, 2026 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (Nasdaq: OKYO), a clinical-stage biopharmaceutical company developing investigational therapies for the treatment of neuropathic... ► Artikel lesen | |
| 07.04. | OKYO Pharma Ltd - 6-K, Report of foreign issuer | 1 | SEC Filings | ||
| 19.03. | OKYO Pharma Announces Chairman and Founder Acquires Shares | 372 | GlobeNewswire (Europe) | LONDON and NEW YORK, March 19, 2026 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (NASDAQ: OKYO), a clinical-stage biopharmaceutical company developing investigational therapies for the treatment of neuropathic... ► Artikel lesen | |
| 19.03. | OKYO Pharma Announces Director Acquires Shares | 427 | GlobeNewswire (Europe) | LONDON and NEW YORK, March 19, 2026 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (NASDAQ: OKYO), a clinical-stage biopharmaceutical company developing investigational therapies for the treatment of neuropathic... ► Artikel lesen | |
| 19.03. | OKYO Pharma Announces Chief Development Officer and Director Acquires Shares | 456 | GlobeNewswire (Europe) | LONDON and NEW YORK, March 19, 2026 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (NASDAQ: OKYO), a clinical-stage biopharmaceutical company developing investigational therapies for the treatment of neuropathic... ► Artikel lesen | |
| 18.03. | OKYO Pharma reports quality of life improvements in pain trial | 2 | Investing.com | ||
| 18.03. | OKYO Pharma Reports New Phase 2 Data Demonstrating Meaningful Improvements in Patient-Reported Quality of Life Outcomes with Urcosimod in Neuropathic Corneal Pain | 399 | GlobeNewswire (Europe) | LONDON and NEW YORK, March 18, 2026 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (Nasdaq: OKYO), a clinical-stage biopharmaceutical company developing investigational therapies for the treatment of neuropathic... ► Artikel lesen | |
| 12.03. | OKYO Pharma Ltd - 6-K, Report of foreign issuer | 1 | SEC Filings | ||
| 23.02. | OKYO Pharma LTD: OKYO Abstract Selected for Presentation at Premier Global Ophthalmology Congress | 320 | GlobeNewswire (Europe) | LONDON and NEW YORK, Feb. 23, 2026 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (Nasdaq: OKYO), a clinical-stage biopharmaceutical company developing investigational therapies for the treatment of neuropathic... ► Artikel lesen | |
| 23.02. | OKYO Pharma Ltd - 6-K, Report of foreign issuer | 3 | SEC Filings | ||
| 20.02. | Piper Sandler startet Coverage für OKYO Pharma mit 'Overweight'-Rating | 3 | Investing.com Deutsch | ||
| 20.02. | Piper Sandler initiates OKYO Pharma stock with Overweight rating | 2 | Investing.com |
1 2 3 4 Weiter >>
68 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| IDEXX LABORATORIES | 486,90 | -0,20 % | XETR NEW INSTRUMENTS AVAILABLE ON XETRA - 18.05.2026 | Folgende Wertpapiere werden in den Handel an folgenden Handelsplätzen (MIC Code) im Quotation Board an der Frankfurter Wertpapierbörse (FWB) aufgenommen. Die Notierung an anderen Handelsplätzen im Quotation... ► Artikel lesen | |
| BIOXCEL THERAPEUTICS | 0,980 | +2,08 % | BioXcel Therapeutics Provides Business Update and Reports First Quarter 2026 Financial Results | FDA accepted sNDA for IGALMI® use in at-home (outpatient) setting; set Nov. 14, 2026, as PDUFA date Advancing BXCL501 as a potential acute treatment for agitation associated with Alzheimer's dementia... ► Artikel lesen | |
| VOYAGER THERAPEUTICS | 3,170 | +9,84 % | Voyager Therapeutics, Inc.: Voyager Receives FDA IND Clearance for VY1706, First Gene Therapy Approach to Reducing Tau Production in the Brain for Alzheimer's Disease | - Dosing of adults with early Alzheimer's disease in clinical trial expected H2 2026 - - Comprehensive preclinical program showed compelling pharmacology and safety profile for VY1706 - - VY1706 uses... ► Artikel lesen | |
| ANAVEX LIFE SCIENCES | 2,213 | -0,98 % | ANAVEX LIFE SCIENCES CORP - Ruhe vor dem Impuls | ||
| PRECISION BIOSCIENCES | 5,490 | -2,66 % | Precision BioSciences, Inc.: Precision BioSciences Announces Late-Breaking Poster Presentation for PBGENE-HBV at European Association for the Study of the Liver Congress 2026 | Late-breaking poster presentation to highlight new biopsy data demonstrating elimination and inactivation of cccDNA from the ongoing Phase 1 ELIMINATE-B trial in chronic hepatitis B
Precision... ► Artikel lesen | |
| CELLAVISION | 11,660 | +3,00 % | Dividendenbekanntmachungen (29.04.2026) | Unternehmen ISIN-Code Dividende (Währung) Dividende (EUR) 2020 BULKERS LTD BMG9156K1018 258,95 NOK 23,7146 EUR ACROW LIMITED AU0000006124 0,02 AUD 0,0122 EUR ADVENICA AB SE0006219473 0... ► Artikel lesen | |
| ZYMEWORKS | 21,120 | +1,20 % | Zymeworks stock price target maintained at $46 by H.C. Wainwright | ||
| VTV THERAPEUTICS | 27,400 | -2,84 % | vTv Therapeutics Inc.: vTv Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4) | ||
| QUOIN PHARMACEUTICALS | 3,900 | +1,56 % | Quoin Pharmaceuticals, Inc.: Quoin Pharmaceuticals Submits IND Application for QRX003 in Peeling Skin Syndrome | -First ever IND submission for this disease, which has no current treatment or cure- -Quoin plans Phase 2 study initiation in 2H 2026- -Submission supported by positive initial clinical data from... ► Artikel lesen | |
| NEUPHORIA THERAPEUTICS | 4,460 | -0,67 % | Neuphoria Therapeutics Inc. - 8-K, Current Report | ||
| PLIANT THERAPEUTICS | 1,022 | +2,82 % | Pliant Therapeutics, Inc.: Pliant Therapeutics Provides Corporate Update and Reports First Quarter 2026 Financial Results | First participant dosed in FORTIFY, a Phase 1b indication expansion trial of PLN-101095Oral presentation at AACR 2026 featured updated data from Phase 1 trial of PLN-101095 showing deepening of confirmed... ► Artikel lesen | |
| MIRA PHARMACEUTICALS | 0,875 | +3,43 % | MIRA Pharmaceuticals Secures Worldwide Exclusive Rights to MIRA-55 and SKNY-1 | Agreement Establishes Global Exclusivity Across MIRA's Core Therapeutic Pipeline and Enhances Strategic Flexibility for Future Licensing and Partnership Opportunities MIAMI, FL / ACCESS Newswire / June... ► Artikel lesen | |
| NUVATION BIO | 4,795 | 0,00 % | Nuvation Bio Inc.: Nuvation Bio Announces FDA Acceptance of Supplemental New Drug Application for IBTROZI (taletrectinib) with Updated Duration of Response in Advanced ROS1-Positive Non-Small Cell Lung Cancer | Application includes updated TRUST-I TKI-naïve median duration of response (mDOR) and median progression-free survival (mPFS) of more than 4 years, as well as TRUST-II... ► Artikel lesen | |
| ONCONETIX | 1,045 | +1,46 % | XFRA J4T: AUSSETZUNG/SUSPENSION | DAS/ DIE FOLGENDE(N) INSTRUMENT(E) IST/ SIND AB SOFORT AUSGESETZT:THE FOLLOWING INSTRUMENT(S) IS/ ARE SUSPENDED WITH IMMEDIATE EFFECT:INSTRUMENT NAME KUERZEL/SHORTCODE ISIN BIS/UNTILONCONETIX NEW DL... ► Artikel lesen | |
| CLENE | 4,940 | +4,22 % | Clene Inc. - S-8, Securities to be offered to employees in employee benefit plans |
Das Unternehmen OKYO PHARMA LIMITED kann der Branche Biotechnologie zugeordnet werden. Die relative Kursveränderung beträgt aktuell -0,62 % bei einem Aktienkurs von 1,610 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu OKYO PHARMA LIMITED finden Sie auf Wallstreet Online.